Top

World Journal of Surgical Oncology

Published in:

01-12-2021 | Ovarian Cancer | Research

The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis

Authors: Lu Ye, Li Cai, Yonghui Fu, Debao Zhuang, Xiaoqing Hu, Youkun Jie

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Background

Venous thromboembolism (VTE) in ovarian cancer (OC) patients has been widely investigated, but our knowledge on the role of VTE in OC patients receiving chemotherapy is limited. The aim of our study was to investigate the prevalence, risk factors, and prognostic value of chemotherapy-associated VTE in OC.

Methods

Three databases (PubMed, Embase, and the Cochrane Library) were systematically searched from inception to October 14, 2020. The primary outcome was the prevalence of VTE in OC patients receiving chemotherapy. The risk factors and prognostic value of VTE were the secondary outcomes. The pooled prevalence of VTE was estimated using the generic inverse-variance method. The statistical heterogeneity was evaluated with Cochran’s Q test and I² statistic. Funnel plot, Begg’s test, and Egger’s test were used to assess the potential publication bias in the meta-analysis.

Results

A total of eleven observational studies with 4759 OC patients were included. The pooled prevalence of VTE was 9% (95% CI, 0.06–0.12) in OC patients receiving chemotherapy. The results of subgroup analysis and sensitivity analysis were basically consistent with the overall pooled estimate. Multiple significant risk factors associated with VTE were also identified including advanced age, D-dimer > 0.5 mg/mL, and tumor diameter > 10 cm. Only two included studies reported the prognostic value of VTE in OC patients receiving chemotherapy, but with inconsistent results. Funnel plot showed that there existed potential publication bias, which was further verified by statistical test, but the results of the trim-and-fill method showed the pooled estimate kept stable after adding two “missing” studies.

Conclusions

This current study revealed that the pooled prevalence of chemotherapy-related VTE in OC was approximately 9% in OC patients. Risk factors for chemotherapy-related VTE were also identified which may contribute to targeting potentially preventative measures for VTE in OC.

Available only for authorised users

Merkow RP, Bilimoria KY, McCarter MD, Cohen ME, Barnett CC, Raval MV, Caprini JA, Gordon HS, Ko CY, Bentrem DJ. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131–7. https://doi.org/10.1097/SLA.0b013e31821b98da.CrossRefPubMed

Ratib S, Walker AJ, Card TR, Grainge MJ. Risk of venous thromboembolism in hospitalised cancer patients in England-a cohort study. J Hematol Oncol. 2016;9(1):60. https://doi.org/10.1186/s13045-016-0291-0.CrossRefPubMedPubMedCentral

Satoh T, Oki A, Uno K, Sakurai M, Ochi H, Okada S, Minami R, Matsumoto K, Tanaka YO, Tsunoda H, Homma S, Yoshikawa H. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97(8):1053–7. https://doi.org/10.1038/sj.bjc.6603989.CrossRefPubMedPubMedCentral

Takasaki K, Miyamoto M, Takano M, Soyama H, Aoyama T, Matsuura H, Iwahashi H, Ishibashi H, Sakamoto T, Furuya K. Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma. Int J Clin Oncol. 2019;24(10):1273–83. https://doi.org/10.1007/s10147-019-01464-4.CrossRefPubMed

Mittal V, Ahuja S, Vejella SS, Stempel JM, Palabindala V, Dourado CM, Leighton JC. Trends and outcomes of venous thromboembolism in hospitalized patients with ovarian cancer: results from nationwide inpatient sample database 2003 to 2011. Int J Gynecol Cancer. 2018;28(8):1478–84. https://doi.org/10.1097/igc.0000000000001335.CrossRefPubMed

Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(Suppl 1):S112–s118. https://doi.org/10.1016/j.thromres.2018.01.028.CrossRefPubMed

Zhou Q, Zhu C, Shen Z, Zhang T, Li M, Zhu J, Qin J, Xie Y, Zhang W, Chen R, Wang G, Qian L, Wu D, Nashan B, Zhou Y. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. Eur J Surg Oncol. 2020. https://doi.org/10.1016/j.ejso.2020.01.026.

Wu X, Xue X, Tang J, Cheng X, Tian W, Jiang R, Zang R. Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23(1):65–72. https://doi.org/10.1097/IGC.0b013e318276dd87.CrossRefPubMed

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(28):3460–73. https://doi.org/10.1200/jco.2016.68.6907.CrossRefPubMed

10.

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, Colombo N. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv1–iv18. https://doi.org/10.1093/annonc/mdy001.CrossRefPubMed

11.

Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015;12:Cd004706. https://doi.org/10.1002/14651858.CD004706.pub5.CrossRef

12.

Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648–55. https://doi.org/10.1002/cncr.27772.CrossRefPubMed

13.

Di Nisio M, Candeloro M, Rutjes AWS, Porreca E. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1336–46. https://doi.org/10.1111/jth.14149.CrossRefPubMed

14.

Fotopoulou C, Karavas A, Trappe R, Chekerov R, Lichtenegger W, Sehouli J. Venous thromboembolism in recurrent ovarian cancer-patients: a systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). Thromb Res. 2009;124(5):531–5. https://doi.org/10.1016/j.thromres.2009.03.013.CrossRefPubMed

15.

Chavan DM, Huang Z, Song K, Parimi LRH, Yang XS, Zhang X, Liu P, Jiang J, Zhang Y, Kong B, Li L. Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer. Medicine. 2017;96(42):e7935. https://doi.org/10.1097/md.0000000000007935.CrossRefPubMedPubMedCentral

16.

Zhang W, Liu X, Cheng H, Yang Z, Zhang G. Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China. Medicine. 2018;97(31):e11754. https://doi.org/10.1097/md.0000000000011754.CrossRefPubMedPubMedCentral

17.

Salinaro JR, McQuillen K, Stemple M, Boccaccio R, Ehrisman J, Lorenzo AM, Havrilesky L, Secord AA, Galvan Turner V, Moore KN, Davidson B. Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2020;30(4):491–7. https://doi.org/10.1136/ijgc-2019-000980.CrossRefPubMed

18.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12. https://doi.org/10.1001/jama.283.15.2008.CrossRefPubMed

19.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

20.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. https://doi.org/10.1016/0197-2456(86)90046-2.CrossRefPubMed

21.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRef

22.

Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206. https://doi.org/10.1037/1082-989x.11.2.193.CrossRefPubMed

23.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefPubMed

24.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.CrossRef

25.

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63. https://doi.org/10.1111/j.0006-341x.2000.00455.x.CrossRefPubMed

26.

Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine. 2019;98(23):e15987. https://doi.org/10.1097/md.0000000000015987.CrossRefPubMedPubMedCentral

27.

Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26(16):2683–9. https://doi.org/10.1200/jco.2008.16.1109.CrossRefPubMed

28.

Mereu L, Tateo S, Klersy C, Martinotti Gabellotti E, Polatti F. Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy. Int J Gynecol Cancer. 2009;19(1):79–83. https://doi.org/10.1111/IGJ.0b013e318199035e.CrossRefPubMed

29.

Guardiola E, Chauffert B, Delroeux D, Royer B, Heyd B, Combe M, Benoit L, Causeret S, Demarchi M, Magnin G, Mayer F, Tixier H, Pivot X. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anti Cancer Drugs. 2010;21(3):320–5. https://doi.org/10.1097/CAD.0b013e328334d953.CrossRefPubMed

30.

Abu Saadeh F, Norris L, O'Toole S, Gleeson N. Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):214–8. https://doi.org/10.1016/j.ejogrb.2013.06.004.CrossRefPubMed

31.

Pant A, Liu D, Schink J, Lurain J. Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy. Int J Gynecol Cancer. 2014;24(6):997–1002. https://doi.org/10.1097/igc.0000000000000164.CrossRefPubMed

32.

Greco PS, Bazzi AA, McLean K, Reynolds RK, Spencer RJ, Johnston CM, Liu JR, Uppal S. Incidence and timing of thromboembolic events in patients with ovarian cancer undergoing neoadjuvant chemotherapy. Obstet Gynecol. 2017;129(6):979–85. https://doi.org/10.1097/aog.0000000000001980.CrossRefPubMed

33.

Kuk A, Magnowska M, Suchy W, Swierczynska J, Zaborowski MP, Gaca M, Nowak-Markwitz E. Retrospective evaluation of thromboembolism risk in ovarian cancer patients treated with bevacizumab. Target Oncol. 2017;12(4):495–503. https://doi.org/10.1007/s11523-017-0496-3.CrossRefPubMedPubMedCentral

34.

Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T, Mikami M. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153(3):589–96. https://doi.org/10.1016/j.ygyno.2019.03.243.CrossRefPubMedPubMedCentral

35.

Althubiti MA, Nour Eldein MM. Trends in the incidence and mortality of cancer in Saudi Arabia. Saudi Med J. 2018;39(12):1259–62. https://doi.org/10.15537/smj.2018.12.23348.CrossRefPubMedPubMedCentral

36.

Pellino G, Sciaudone G, Candilio G, De Fatico GS, Canonico S, Selvaggi F. Predictors of venous thromboembolism after colorectal surgery in a single unit. Acta Chir Belg. 2015;115(4):288–92. https://doi.org/10.1080/00015458.2015.11681114.CrossRefPubMed

37.

Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019;133(4):291–8. https://doi.org/10.1182/blood-2018-08-835595.CrossRefPubMed

38.

Stampfli SF, Akhmedov A, Gebhard C, Lohmann C, Holy EW, Rozenberg I, Spescha R, Shi Y, Luscher TF, Tanner FC, Camici GG. Aging induces endothelial dysfunction while sparing arterial thrombosis. Arterioscler Thromb Vasc Biol. 2010;30(10):1960–7. https://doi.org/10.1161/atvbaha.110.206920.CrossRefPubMed

39.

Bhayadia R, Schmidt BM, Melk A, Homme M. Senescence-induced oxidative stress causes endothelial dysfunction. J Gerontol Ser A Biol Sci Med Sci. 2016;71(2):161–9. https://doi.org/10.1093/gerona/glv008.CrossRef

40.

Hosokawa Y, Takao W, Itagaki H, Nishida K, Akiyama A, Shikama A, Ochi H, Satoh T, Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E. Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. J Obstet Gynaecol Res. 2019;22(5):988–98 https://doi.org/10.1111/jog.14233. https://doi.org/10.1007/s10120-019-00930-2.

41.

Kodama J, Seki N, Fukushima C, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y. Elevated preoperative plasma D-dimer levels and the incidence of venous thromboembolism in Japanese females with gynecological cancer. Gastric Cancer. 2013;5(1):299–304 https://doi.org/10.1007/s10120-019-00930-2. https://doi.org/10.3892/ol.2012.970.

42.

Tasaka N, Minaguchi T. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer; 2020. https://doi.org/10.1111/jog.14233.CrossRef

43.

Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X. Clinical significance of plasma D-dimer in ovarian cancer: a meta-analysis. Medicine (Baltimore). 2017;96(25):e7062. https://doi.org/10.1097/MD.0000000000007062.CrossRef

44.

Tan L, Qi B, Yu T, Wang C. Incidence and risk factors for venous thromboembolism following surgical treatment of fractures below the hip: a meta-analysis. Int Wound J. 2016;13(6):1359–71. https://doi.org/10.1111/iwj.12533.CrossRefPubMedPubMedCentral

45.

Blondon M, Casini A, Hoppe KK, Boehlen F, Righini M, Smith NL. Risks of venous thromboembolism after cesarean sections: a meta-analysis. Chest. 2016;150(3):572–96. https://doi.org/10.1016/j.chest.2016.05.021.CrossRefPubMed

46.

Wattanakit K, Lutsey PL, Bell EJ, Gornik H, Cushman M, Heckbert SR, Rosamond WD, Folsom AR. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost. 2012;108(3):508–15. https://doi.org/10.1160/th11-10-0726.CrossRefPubMedPubMedCentral

47.

Zamani A, Omrani GR, Lankarani KB. Hyperhomocysteinaemia, hyperlipidaemia and risk of venous thromboembolism in Shiraz. East Mediterr Health J. 2003;9(5-6):935–43.PubMed

Title: The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis
Authors: Lu Ye
Li Cai
Yonghui Fu
Debao Zhuang
Xiaoqing Hu
Youkun Jie
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-020-02101-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Laparoscopic intragastric resection of gastric synovial sarcoma: report of the first ever case with video demonstration

The Amplatzer device and pedicle muscle flap transposition for the treatment of bronchopleural fistula with chronic empyema after lobectomy: two case reports

Geriatric nutritional risk index predicts cancer prognosis in patients with local advanced rectal cancer undergoing chemoradiotherapy followed by curative surgery